Trials / Completed
CompletedNCT05318937
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Effects of SAGE-718 in Parkinson's Disease Cognitive Impairment
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Supernus Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 50 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the effect of SAGE-718 on cognitive performance in participants with Parkinson's disease mild cognitive impairment (PD-MCI).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SAGE-718-matching placebo | Oral capsules |
| DRUG | SAGE-718 | Oral capsules |
Timeline
- Start date
- 2022-06-06
- Primary completion
- 2024-01-17
- Completion
- 2024-02-23
- First posted
- 2022-04-08
- Last updated
- 2025-09-12
- Results posted
- 2025-02-06
Locations
38 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05318937. Inclusion in this directory is not an endorsement.